Plain-English translation of NCT05759078 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called ferric carboxymaltose, given as an infusion into your vein, to see if it can help people recover better after a heart attack. You'll receive either the active medication or a placebo (a salt water infusion that looks the same but has no medication), and researchers will track whether the treatment reduces your risk of death, heart failure complications, and improves your overall quality of life over up to three years.
After a heart attack, many patients develop iron deficiency, which may increase the risk of heart failure and other serious complications. This medication is being tested to see whether correcting iron deficiency can protect your heart and help you feel better.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the iron medication or placebo as a 15-minute intravenous infusion. You'll then be followed for a minimum of 8 months up to 3 years with regular visits to check your heart health, blood work, and quality of life. Throughout the study, researchers will monitor whether you experience any heart-related events or complications and compare outcomes between the two groups.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
Poland